Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.92 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.45 |
| ▸ | ITGB2 | P05107 | 3/20 | 0.44 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.44 |
| ▸ | ITGAL | P20701 | 3/20 | 0.44 |
| ▸ | GHSR | Q92847 | 1/20 | 0.44 |
| ▸ | CPB1 | P15086 | 1/20 | 0.43 |
| ▸ | REN | P00797 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30175135 | 0.96 | SLC15A2 (1.00) | SLC15A2CPB2SLC6A5ITGB2ICAM1 | |
| SCHEMBL19087235 | 0.96 | SLC15A2 (1.00) | SLC15A2CPB2SLC6A5ITGB2ICAM1 | |
| SCHEMBL22462015 | 0.96 | SLC15A2 (1.00) | SLC15A2CPB2SLC6A5ITGB2ICAM1 | |
| SCHEMBL28851961 | 0.95 | SLC15A2 (0.98) | SLC15A2CPB2SLC6A5ITGB2ICAM1 | |
| SCHEMBL25354642 | 0.95 | SLC15A2 (0.98) | SLC15A2CPB2SLC6A5ITGB2ICAM1 | |
| Acetic Acid SCHEMBL31696243 | 0.93 | SLC15A2 (0.94) | SLC15A2CPB2SLC6A5ITGB2ICAM1 | |
| SCHEMBL29349986 | 0.93 | SLC15A2 (0.94) | SLC15A2CPB2SLC6A5ITGB2ICAM1 | |
| Acetic Acid SCHEMBL29360257 | 0.92 | SLC15A2 (0.92) | SLC15A2CPB2SLC6A5ITGB2ICAM1 | |
| SCHEMBL29351224 | 0.92 | SLC15A2 (0.92) | SLC15A2CPB2SLC6A5ITGB2ICAM1 | |
| SCHEMBL29397091 | 0.87 | SLC15A2 (0.82) | SLC15A2CPB2SLC6A5ITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694932-A2 | COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS | Protomer Technologies Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250359433-A1 | DISPLAY DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2025-11-20 | — | — | US | disclosed |
| US-12376454-B2 | Display device having pixel electrode overlapping transistor semiconductor layer | SAMSUNG DISPLAY CO., LTD. (KR) | 2025-07-29 | — | — | US | disclosed |
| CN-114258399-B | Protein container, polynucleotide, vector, expression cassette, cell, method for producing container, method for identifying pathogen or diagnosing disease, use of container, and diagnostic kit | 奥斯瓦道·克鲁兹基金会 | 2025-06-24 | — | — | CN | disclosed |
| CN-112740044-B | Method for diagnosis or prognosis of neurological disorders | 阿尔斯特创新有限公司 | 2025-04-11 | — | — | CN | disclosed |
| WO-2025076422-A1 | REGULATED EXPRESSION OF CARD11-PIK3R3 FUSION PROTEIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | UNIVERSITY OF WASHINGTON | 2025-04-03 | — | — | US | disclosed |
| CN-116003542-B | Microorganism for producing citric acid, construction method and application thereof | 中国科学院天津工业生物技术研究所 | 2025-03-14 | — | — | CN | disclosed |
| CN-114751989-B | Antigen binding molecules comprising trimeric TNF family ligands | 豪夫迈·罗氏有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-112771166-B | CAR-expressing T cells and CAR expression vectors | 诺伊尔免疫生物科技株式会社 | 2025-03-04 | — | — | CN | disclosed |
| CN-114401730-A | Immunomodulatory compositions and methods | 因内特生物制品有限责任公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-114395018-A | Use of CifA and CifB muteins for modulating cytoplasmic incompatibility | 天津大学 | 2022-04-26 | — | — | CN | disclosed |
| CN-114369145-A | Mutant genes and proteins of cytoplasmic incompatibility factor CifA or CifB | 天津大学 | 2022-04-19 | — | — | CN | disclosed |
| CN-107073095-B | Acinetobacter baumannii vaccine based on lipopolysaccharide-deleted cell components | 瓦克斯丁公司 | 2022-04-19 | — | — | CN | disclosed |
| US-20220115480-A1 | DISPLAY DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-04-14 | — | — | US | disclosed |
| CN-114269785-A | Immunostimulatory multimeric binding molecules | IGM生物科学股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-114252628-A | Application of urine regeneration protein and polypeptide fragment thereof in allergic diseases | 首都医科大学附属北京世纪坛医院 | 2022-03-29 | — | — | CN | disclosed |
| CN-114258399-A | Protein container, polynucleotide, vector, expression cassette, cell, method for producing container, method for identifying pathogen or diagnosing disease, use of container, and diagnostic kit | 奥斯瓦道·克鲁兹基金会 | 2022-03-29 | — | — | CN | disclosed |
| CN-107207579-B | Antigen binding molecules comprising trimeric TNF family ligands | 豪夫迈·罗氏有限公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-107614695-B | Methods of treating obesity and non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with glucagon receptor antagonist antibodies | 瑞美德生物医药科技有限公司 | 2022-01-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | DHFR, CCNH, ODC1 | SLC15A2 3554/4885CPB2 2907/4885SLC6A5 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.